Search Results for “EC” – Page 242 – media

Multinational companies target the trillion-dollar medical equipment “trade-in” market

“The introduction of the ‘old for new’ policy is good news for the entire medical market, especially for companies like us that have been rooted in China for many years.” Pu Zhengrong, vice president of Siemens Healthineers Greater China and head of clinical treatment systems, expressed the above views in an interview with China News Service recently. At the 89th China International Medical Equipment (Spring) Fair (CMEF) which just ended in Shanghai, the “old for new” policy for medical equipment was undoubtedly a hot topic. Faced with the trillion-level market released by this policy, a number of multinational companies showed great interest. Chen Jinlei, vice president of GE Healthcare China and general manager of medical imaging business, said that after the “old for new” policy was released, the medical industry, from users to manufacturers, paid close attention to it. “We have developed eight targeted plans for ‘old for new’.” On ...
- Source: drugdu
- 77
- June 1, 2024
Fresenius Medical Care plans layoffs ahead of California plant closure

Dive Brief Fresenius Medical Care will lay off more than 300 people as part of a planned closure of a manufacturing plant in Concord, California. The cuts will begin in August and continue through mid-2025, according to a Worker Adjustment and Retraining Notification (WARN) filing with California. CEO Helen Giza told investors on a May 7 call that the company is moving production from California to Mexico to reduce costs and improve margins. Dive Insight Fresenius Medical Care, which makes dialysis equipment and operates dialysis centers around the world, is looking to tighten spending in its first year as an independent company. The firm was separated from parent company Fresenius in November, with Fresenius keeping a 32% stake. Giza told investors that “several initiatives are underway” to optimize Fresenius Medical Care’s manufacturing footprint and supply chain. The company will move all dialysis manufacturing operations from Concord, California, to a facility ...
- Source: drugdu
- 105
- June 1, 2024
Innovative Test Improves Assessment of Patients with Mild Traumatic Brain Injury

Traumatic brain injury (TBI) occurs when external mechanical energy is transferred to brain tissue, causing cellular damage, dysfunction, and dysregulation. It is a significant public health issue, being a leading cause of death and disability globally, with approximately 69 million people affected each year. For clinicians assessing these patients, it is crucial to quickly ascertain the presence or absence of potentially life-threatening hemorrhages and neurological complications. TBI severity is evaluated using the Glasgow Coma Scale (GCS) and categorized as mild, moderate, or severe. Mild traumatic brain injuries (mTBI) are the most common, comprising 70-90% of all TBI cases, and they are the least likely to lead to acute medical emergencies. It is noted that about 90% of mTBI patients who receive computed tomography (CT) scans show no abnormal findings. Despite this, an estimated 82% of all TBI patients are scanned, many of which could potentially be unnecessary. These scans not ...
- Source: drugdu
- 86
- May 31, 2024
New Method for Lung Microbiomes Analysis Predicts Mortality in Children after Bone Marrow Transplant

Bone marrow transplant, also referred to as hematopoietic cell transplantation (HCT), serves as a critical treatment for children with leukemia, bone marrow failure, and various genetic disorders, including inborn immunodeficiencies and sickle-cell disease. However, the procedure is intense, involving high doses of chemotherapy to eradicate diseased cells in the bone marrow. This treatment suppresses the immune system to allow healthy stem cells to grow, which are then transplanted into the patients. Due to this immune suppression, patients become highly susceptible to viruses, bacteria, and other pathogens during the critical phase when their immune system is “rebooting.” Lung infections are especially prevalent among these patients, affecting up to 40% of pediatric HCT recipients. When these infections require ventilator support, the mortality rate can be as high as 50%. Identifying the specific pathogens involved is challenging because doctors using conventional diagnostic tests may not be able to target the correct ones, given ...
- Source: drugdu
- 141
- May 31, 2024
Johnson & Johnson Acquires Numab’s Investigational Antibody for the Treatment of Atopic Dermatitis

Don Tracy, Associate Editor The acquisition of a novel therapy for atopic dermatitis includes an all-cash transaction totaling approximately $1.25 billion. Image Credit: Adobe Stock Images/Ityuan Johnson & Johnson (J&J) announced that it has agreed to terms with Numab Therapeutics to acquire its wholly owned subsidiary for the global rights to NM26, an investigational bispecific antibody currently in Phase II of development for the treatment of atopic dermatitis (AD). Under terms of the deal, J&J will pay Numab around $1.25 billion in an all-cash transaction. According to the company, the transaction is expected to close later this year, clearance under the Hart-Scott-Rodino Antitrust Improvements Act and fulfillment of customary closing conditions. NM26 targets two established pathways, interleukin (IL)-4Rα and IL-31, in AD. According to investigators, this works by targeting IL-4Rα, which is responsible for Th2-mediated skin inflammation, and IL-31, which triggers skin itch and exacerbates AD. Additionally, NM26 has demonstrated ...
- Source: drugdu
- 72
- May 31, 2024
Entod Pharma launches Vitamin D3 eye drops

Entod Pharmaceuticals has launched Vitamin D3 enriched lubricating eye drops. These novel formulations aim to benefit ocular health, providing targeted relief for individuals suffering from dry eyes. Vitamin D3 has now been incorporated into some of Entod’s selected lubricant eye drop brands that are currently prescribed by eye doctors for dry eyes. Dry eye syndrome is a prevalent condition characterised by discomfort, irritation, and even vision impairment. The main causes of dry eyes are environmental factors, Vitamin deficiencies, Poor blinking habits, Contact lenses, Digital devices, Smoking, Refractive surgeries and more. Commenting on the launch, Nikkhil K Masurkar, CEO, Entod said, “ Adding Vitamin D3 to routine dry eye treatment improves ocular surface hemostasis parameters, results in better tear stability, improves tear osmolarity, and helps modulate corneal wound healing. Vitamin D3 enriched lubricating eye drops would only be available through health care professional prescriptions.” Emphasising the significance of Vitamin D on ...
- Source: drugdu
- 73
- May 31, 2024
Glenmark creates mass awareness around Hypertension

Glenmark Pharmaceuticals, marked the month of May as the ‘Hypertension Awareness Month’ by reportedly partnering with more than 1000 healthcare professionals (HCPs) from 250+ cities and towns across the country, and organised 400+ public awareness rallies and screening camps to create mass awareness around Hypertension (High Blood Pressure). The rallies consisted of general informative sessions led by HCPs, who provided detailed insights on the signs, symptoms, and preventive measures related to Hypertension. Subsequently, blood pressure screening camps were set up to offer the general public an opportunity to assess their blood pressure levels. Reportedly, as a result of this initiative, Glenmark successfully reached out to 6 million adults, effectively raising awareness about the disease. Hypertension, a prevalent cardiovascular disease (CVD) risk factor, affects approximately 35.5 per cent of adults in India. Alarmingly, CVD is the leading cause of death in the country, responsible for almost one-fourth of all mortality cases. ...
- Source: drugdu
- 78
- May 31, 2024
Merck KGaA announces its largest investment in Asia

Merck KGaA Darmstadt Germany announced its largest investment in Asia through a ceremony of its € 300 million Bioprocessing Production Center in Daejeon, South Korea. The new facility will accelerate the biotech and pharmaceutical industry’s development by manufacturing vaccines, cell and gene therapies, and protein-based therapies. Once completed, the investment aims to create as many as 300 new jobs and continue to grow and support global demand for critical drugs and therapies. The ceremony witnessed the presence of the leadership team of Merck including Matthias Heinzel- CEO of the Life Science business, Karen Madden- Chief Technology Officer, Life Science business, Sebastián Arana- Head, Process Solutions, Life Science business, Ivan Donzelot- Head of Integrated Supply Chain Operations. They were joined by Cheong Inkyo, Trade Minister of Korea, Lee Jang Woo, Mayor of Daejeon, Ambassador Georg Schmidt along with other dignitaries and partners.
- Source: drugdu
- 84
- May 31, 2024
New AI Transparency Rule Should Drive Higher Quality Tools & More AI Adoption

Micky Tripathi, head of The Office of the National Coordinator for Health Information Technology (ONC), thinks his office’s recent rule on AI transparency will do a good job of empowering both providers and tech developers. “I think it’s going to spur more adoption of AI-based tools in healthcare delivery, and hopefully, it’s going to establish a sort of mechanism for driving higher quality AI-based tools,” he stated during an interview this month at the Reuters Digital Health conference in San Diego. In December, the ONC finalized a new rule that instated transparency requirements for the use of AI in healthcare settings. It requires healthcare AI developers to provide more data about their products to customers, which could aid providers in determining AI tools’ risks and effectiveness. Under the new rule, AI vendors must share information about how their software works and how it was developed. That means disclosing information about ...
- Source: drugdu
- 113
- May 30, 2024
Insmed’s Trial Results Pave Way for FDA Filing in a Lung Disease With No Approved Therapies

Brensocatib, a drug Insmed licensed from AstraZeneca, met the main goal of a Phase 3 test in non-cystic fibrosis bronchiectasis. Insmed plans to seek regulatory approvals in this indication while also continuing to develop the small molecule for other inflammatory disorders. By Frank VinluanAn Insmed drug developed for a serious chronic lung disorder with no FDA-approved therapies handily beat a placebo in a pivotal clinical trial, preliminary results that set the stage for a regulatory submission planned for later this year. It could be the first of several. The drug is also in development for other inflammatory conditions, giving the drug multiple opportunities to achieve its blockbuster potential. The first disease target of the Insmed drug is non-cystic fibrosis bronchiectasis (NCFB), a chronic lung disease characterized by excess production of sputum that’s persistently coughed up from the respiratory tract. Patients who have NCFB also experience frequent respiratory infections. There’s no ...
- Source: drugdu
- 94
- May 30, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.